IOVS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dueñas, Z.
Right arrow Articles by Carmen, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dueñas, Z.
Right arrow Articles by Carmen, C.
(Investigative Ophthalmology and Visual Science. 1999;40:2498-2505.)
© 1999 by The Association for Research in Vision and Ophthalmology, Inc.

Inhibition of Rat Corneal Angiogenesis by 16-kDa Prolactin and by Endogenous Prolactin-like Molecules

Zulma Dueñas1,2, Luz Torner1, Ana M. Corbacho1, Alejandra Ochoa1, Gabriel Gutiérrez–Ospina1, Fernando López–Barrera1, Fernando A. Barrios1, Peter Berger2, Gonzalo Martínez de la Escalera1 and CarmenClapp 1

1 From the Neurobiology Center, National Autonomous University of Mexico, Querétaro, Mexico; and the 2 Institute for Biomedical Aging Research, Austrian Academy of Sciences, Innsbruck, Austria.

PURPOSE. The cornea is an avascular organ, where induction of new blood vessels involves the turn-on of proangiogenic factors and/or the turn-off of antiangiogenic regulators. Prolactin (PRL) fragments of 14 kDa and 16 kDa bind to endothelial cell receptors and inhibit angiogenesis. This study was designed to determine whether antiangiogenic PRL-like molecules are involved in cornea avascularity.

METHODS. Sixteen-kDa PRL and basic fibroblast growth factor (bFGF) or anti-PRL antibodies were placed into rat cornea micropockets and neovascularization evaluated by the optical density associated with capillaries stained by the peroxidase reaction and by the number of vessels growing into the implants. Prolactin receptors in corneal epithelium were investigated by immunocytochemistry.

RESULTS. bFGF induced a dose-dependent stimulation of corneal neovascularization. This effect was inhibited by coadministration of 16-kDa PRL, as indicated by a 65% reduction in vessel density and a 50% decrement in the incidence of angiogenic responses. Corneal angiogenic reactions of different intensities were induced by implantation of polyclonal and monoclonal anti-PRL antibodies. Corneal epithelial cells were labeled by several anti-PRL receptor monoclonal antibodies.

CONCLUSIONS. These findings show that exogenous 16-kDa PRL inhibits bFGF-induced corneal neovascularization and suggest that PRL-like molecules with antiangiogenic actions function in the cornea. PRL receptors in the corneal epithelium may imply that PRL in the cornea derives from lacrimal PRL internalized through an intracellular pathway. These observations are consistent with the notion that members of the PRL family are potential regulators of corneal angiogenesis.




This article has been cited by other articles:


Home page
Cancer Res.Home page
S.-H. Lee, J. Kunz, S.-H. Lin, and L.-y. Yu-Lee
16-kDa Prolactin Inhibits Endothelial Cell Migration by Down-Regulating the Ras-Tiam1-Rac1-Pak1 Signaling Pathway
Cancer Res., November 15, 2007; 67(22): 11045 - 11053.
[Abstract] [Full Text] [PDF]


Home page
J. Cell Sci.Home page
Y. Macotela, M. B. Aguilar, J. Guzman-Morales, J. C. Rivera, C. Zermeno, F. Lopez-Barrera, G. Nava, C. Lavalle, G. M. de la Escalera, and C. Clapp
Matrix metalloproteases from chondrocytes generate an antiangiogenic 16 kDa prolactin
J. Cell Sci., May 1, 2006; 119(9): 1790 - 1800.
[Abstract] [Full Text] [PDF]


Home page
Endocr Relat CancerHome page
E. Ueda, U. Ozerdem, Y.-H. Chen, M. Yao, K. T. Huang, H. Sun, M. Martins-Green, P. Bartolini, and A. M Walker
A molecular mimic demonstrates that phosphorylated human prolactin is a potent anti-angiogenic hormone.
Endocr. Relat. Cancer, March 1, 2006; 13(1): 95 - 111.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
S.-h. Lee, M. Nishino, T. Mazumdar, G. E. Garcia, M. Galfione, F. L. Lee, C. L. Lee, A. Liang, J. Kim, L. Feng, et al.
16-kDa Prolactin Down-Regulates Inducible Nitric Oxide Synthase Expression through Inhibition of the Signal Transducer and Activator of Transcription 1/IFN Regulatory Factor-1 Pathway
Cancer Res., September 1, 2005; 65(17): 7984 - 7992.
[Abstract] [Full Text] [PDF]


Home page
IOVSHome page
J. Aranda, J. C. Rivera, M. C. Jeziorski, J. Riesgo-Escovar, G. Nava, F. Lopez-Barrera, H. Quiroz-Mercado, P. Berger, G. Martinez de la Escalera, and C. Clapp
Prolactins Are Natural Inhibitors of Angiogenesis in the Retina
Invest. Ophthalmol. Vis. Sci., August 1, 2005; 46(8): 2947 - 2953.
[Abstract] [Full Text] [PDF]


Home page
J EndocrinolHome page
K Horiguchi, S Yagi, K Ono, Y Nishiura, M Tanaka, M Ishida, and T Harigaya
Prolactin gene expression in mouse spleen helper T cells
J. Endocrinol., December 1, 2004; 183(3): 639 - 646.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
C. Gonzalez, A. M. Corbacho, J. P. Eiserich, C. Garcia, F. Lopez-Barrera, V. Morales-Tlalpan, A. Barajas-Espinosa, M. Diaz-Munoz, R. Rubio, S.-H. Lin, et al.
16K-Prolactin Inhibits Activation of Endothelial Nitric Oxide Synthase, Intracellular Calcium Mobilization, and Endothelium-Dependent Vasorelaxation
Endocrinology, December 1, 2004; 145(12): 5714 - 5722.
[Abstract] [Full Text] [PDF]


Home page
IOVSHome page
Z. Duenas, J. C. Rivera, H. Quiroz-Mercado, J. Aranda, Y. Macotela, P. M. de Oca, F. Lopez-Barrera, G. Nava, J. L. Guerrero, A. Suarez, et al.
Prolactin in Eyes of Patients with Retinopathy of Prematurity: Implications for Vascular Regression
Invest. Ophthalmol. Vis. Sci., July 1, 2004; 45(7): 2049 - 2055.
[Abstract] [Full Text] [PDF]


Home page
IOVSHome page
H. Pan, N.-Q.-N. Nguyen, H. Yoshida, F. Bentzien, L. C. Shaw, F. Rentier-Delrue, J. A. Martial, R. Weiner, I. Struman, and M. B. Grant
Molecular Targeting of Antiangiogenic Factor 16K hPRL Inhibits Oxygen-Induced Retinopathy in Mice
Invest. Ophthalmol. Vis. Sci., July 1, 2004; 45(7): 2413 - 2419.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
J. Kim, W. Luo, D.-T. Chen, K. Earley, J. Tunstead, L.-Y. Yu-Lee, and S.-H. Lin
Antitumor Activity of the 16-kDa Prolactin Fragment in Prostate Cancer
Cancer Res., January 15, 2003; 63(2): 386 - 393.
[Abstract] [Full Text] [PDF]


Home page
Arch OphthalmolHome page
B. K. Ambati, A. M. Joussen, J. Ambati, Y. Moromizato, C. Guha, K. Javaherian, S. Gillies, M. S. O'Reilly, and A. P. Adamis
Angiostatin Inhibits and Regresses Corneal Neovascularization
Arch Ophthalmol, August 1, 2002; 120(8): 1063 - 1068.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
F. Bentzien, I. Struman, J.-F. Martini, J. Martial, and R. Weiner
Expression of the Antiangiogenic Factor 16K hPRL in Human HCT116 Colon Cancer Cells Inhibits Tumor Growth in Rag1-/- Mice
Cancer Res., October 1, 2001; 61(19): 7356 - 7362.
[Abstract] [Full Text] [PDF]


Home page
IOVSHome page
A. Ochoa, P. Montes de Oca, J. C. Rivera, Z. Dueñas, G. Nava, G. M. de la Escalera, and C. Clapp
Expression of Prolactin Gene and Secretion of Prolactin by Rat Retinal Capillary Endothelial Cells
Invest. Ophthalmol. Vis. Sci., June 1, 2001; 42(7): 1639 - 1645.
[Abstract] [Full Text]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
D. Coss, L. Yang, C. B. Kuo, X. Xu, R. A. Luben, and A. M. Walker
Effects of prolactin on osteoblast alkaline phosphatase and bone formation in the developing rat
Am J Physiol Endocrinol Metab, December 1, 2000; 279(6): E1216 - E1225.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1999 by the Association for Research in Vision and Ophthalmology